These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

326 related items for PubMed ID: 28784674

  • 1. Comparative Pharmacodynamics of Single-Dose Oritavancin and Daily High-Dose Daptomycin Regimens against Vancomycin-Resistant Enterococcus faecium Isolates in an In Vitro Pharmacokinetic/Pharmacodynamic Model of Infection.
    Belley A, Lalonde-Séguin D, Arhin FF, Moeck G.
    Antimicrob Agents Chemother; 2017 Oct; 61(10):. PubMed ID: 28784674
    [Abstract] [Full Text] [Related]

  • 2. Evaluation of Oritavancin Dosing Strategies against Vancomycin-Resistant Enterococcus faecium Isolates with or without Reduced Susceptibility to Daptomycin in an In Vitro Pharmacokinetic/Pharmacodynamic Model.
    Belley A, Arhin FF, Moeck G.
    Antimicrob Agents Chemother; 2018 Jan; 62(1):. PubMed ID: 29109163
    [Abstract] [Full Text] [Related]

  • 3. Time-kill kinetics of oritavancin and comparator agents against Staphylococcus aureus, Enterococcus faecalis and Enterococcus faecium.
    McKay GA, Beaulieu S, Arhin FF, Belley A, Sarmiento I, Parr T, Moeck G.
    J Antimicrob Chemother; 2009 Jun; 63(6):1191-9. PubMed ID: 19369269
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Evaluation of the novel combination of daptomycin plus ceftriaxone against vancomycin-resistant enterococci in an in vitro pharmacokinetic/pharmacodynamic simulated endocardial vegetation model.
    Hall Snyder A, Werth BJ, Barber KE, Sakoulas G, Rybak MJ.
    J Antimicrob Chemother; 2014 Aug; 69(8):2148-54. PubMed ID: 24777900
    [Abstract] [Full Text] [Related]

  • 6. In vitro stepwise selection of reduced susceptibility to lipoglycopeptides in enterococci.
    Arhin FF, Seguin DL, Belley A, Moeck G.
    Diagn Microbiol Infect Dis; 2017 Oct; 89(2):168-171. PubMed ID: 28733126
    [Abstract] [Full Text] [Related]

  • 7. Vancomycin-resistant Enterococcus faecium in Algeria: phenotypic and genotypic characterization of clinical isolates.
    Benamrouche N, Guettou B, Henniche FZ, Assaous F, Laouar H, Ziane H, Djennane F, Tiouit D, Bentchouala C, Yamouni F, Rahal K, Tali Maamar H.
    J Infect Dev Ctries; 2021 Jan 31; 15(1):95-101. PubMed ID: 33571151
    [Abstract] [Full Text] [Related]

  • 8. Oritavancin Combinations with β-Lactams against Multidrug-Resistant Staphylococcus aureus and Vancomycin-Resistant Enterococci.
    Smith JR, Yim J, Raut A, Rybak MJ.
    Antimicrob Agents Chemother; 2016 Apr 31; 60(4):2352-8. PubMed ID: 26833159
    [Abstract] [Full Text] [Related]

  • 9. 1,2,4-Oxadiazole antimicrobials act synergistically with daptomycin and display rapid kill kinetics against MDR Enterococcus faecium.
    Carter GP, Harjani JR, Li L, Pitcher NP, Nong Y, Riley TV, Williamson DA, Stinear TP, Baell JB, Howden BP.
    J Antimicrob Chemother; 2018 Jun 01; 73(6):1562-1569. PubMed ID: 29518208
    [Abstract] [Full Text] [Related]

  • 10. Establishment and Persistence of Glycopeptide-Resistant Enterococcus faecium ST80 and ST117 Clones Within a Health Care Facility Located in a Low-Prevalence Geographical Region.
    Rodríguez-Lucas C, Fernández J, Raya C, Bahamonde A, Quiroga A, Muñoz R, Rodicio MR.
    Microb Drug Resist; 2022 Feb 01; 28(2):217-221. PubMed ID: 34705570
    [Abstract] [Full Text] [Related]

  • 11. Daptomycin: A viable therapeutic option for vancomycin-resistant enterococcal urinary-tract infections in Indian medical settings?
    Mohan B, Garg S, Appannanavar SB, Taneja N.
    Indian J Med Microbiol; 2016 Feb 01; 34(3):398-9. PubMed ID: 27514977
    [No Abstract] [Full Text] [Related]

  • 12. Emergence of daptomycin non-susceptibility in colonizing vancomycin-resistant Enterococcus faecium isolates during daptomycin therapy.
    Lellek H, Franke GC, Ruckert C, Wolters M, Wolschke C, Christner M, Büttner H, Alawi M, Kröger N, Rohde H.
    Int J Med Microbiol; 2015 Dec 01; 305(8):902-9. PubMed ID: 26454536
    [Abstract] [Full Text] [Related]

  • 13. Dalbavancin is active in vitro against biofilms formed by dalbavancin-susceptible enterococci.
    Neudorfer K, Schmidt-Malan SM, Patel R.
    Diagn Microbiol Infect Dis; 2018 Jan 01; 90(1):58-63. PubMed ID: 29195766
    [Abstract] [Full Text] [Related]

  • 14. In vitro activity of oritavancin alone or in combination against vancomycin-susceptible and -resistant enterococci.
    Wu T, Meyer K, Harrington AT, Danziger LH, Wenzler E.
    J Antimicrob Chemother; 2019 May 01; 74(5):1300-1305. PubMed ID: 30753495
    [Abstract] [Full Text] [Related]

  • 15. Institution-wide and Within-Patient Evolution of Daptomycin Susceptibility in Vancomycin-Resistant Enterococcus faecium Bloodstream Infections.
    Woods RJ, Patel TS, Nagel JL, Newton DW, Read AF.
    Infect Control Hosp Epidemiol; 2018 Feb 01; 39(2):226-228. PubMed ID: 29331166
    [Abstract] [Full Text] [Related]

  • 16. In vitro activity of oritavancin and comparator agents against staphylococci, streptococci and enterococci from clinical infections in Europe and North America, 2011-2014.
    Biedenbach DJ, Arhin FF, Moeck G, Lynch TF, Sahm DF.
    Int J Antimicrob Agents; 2015 Dec 01; 46(6):674-81. PubMed ID: 26541881
    [Abstract] [Full Text] [Related]

  • 17. Antimicrobial susceptibility of bacteremic vancomycin-resistant Enterococcus faecium to eravacycline, omadacycline, lipoglycopeptides, and other comparator antibiotics: Results from the 2019-2020 Nationwide Surveillance of Multicenter Antimicrobial Resistance in Taiwan (SMART).
    Tsai HY, Lee YL, Liu PY, Lu MC, Shao PL, Lu PL, Cheng SH, Ko WC, Lin CY, Wu TS, Yen MY, Wang LS, Liu CP, Lee WS, Shi ZY, Chen YS, Wang FD, Tseng SH, Chen YH, Sheng WH, Lee CM, Chen YH, Liao CH, Hsueh PR.
    Int J Antimicrob Agents; 2021 Jul 01; 58(1):106353. PubMed ID: 33961991
    [Abstract] [Full Text] [Related]

  • 18. Pharmacodynamics of a simulated single 1,200-milligram dose of oritavancin in an in vitro pharmacokinetic/pharmacodynamic model of methicillin-resistant staphylococcus aureus infection.
    Belley A, Arhin FF, Sarmiento I, Deng H, Rose W, Moeck G.
    Antimicrob Agents Chemother; 2013 Jan 01; 57(1):205-11. PubMed ID: 23089749
    [Abstract] [Full Text] [Related]

  • 19. Impact of Daptomycin Dose Exposure Alone or in Combination with β-Lactams or Rifampin against Vancomycin-Resistant Enterococci in an In Vitro Biofilm Model.
    Jahanbakhsh S, Singh NB, Yim J, Kebriaei R, Smith JR, Lev K, Tran TT, Rose WE, Arias CA, Rybak MJ.
    Antimicrob Agents Chemother; 2020 Apr 21; 64(5):. PubMed ID: 32094136
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.